Marie-Anne Damiette Smit

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group

Stuart M. Lichtman, R. Donald Harvey, Marie-Anne Damiette Smit et al. · Journal of Clinical Oncology · 2017 · 175 citations

Pharmacy, Oncology, Cancer Control +9

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

Albiruni RA Razak, James M. Cleary, Víctor Moreno et al. · Journal for ImmunoTherapy of Cancer · 2020 · 118 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.

Bhagirathbhai Dholaria, Katja Weisel, María‐Victoria Mateos et al. · Journal of Clinical Oncology · 2023 · 63 citations

Medicine, Pharmacology, Pharmacotherapy +17

Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).

Lauren A. Byers, Alberto Chiappori, Marie-Anne Damiette Smit · Journal of Clinical Oncology · 2019 · 32 citations

Medicine, Oncology, Pharmacology +13

A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).

Paula Rodríguez‐Otero, Anita D’Souza, Donna Reece et al. · Journal of Clinical Oncology · 2022 · 29 citations

Life Sciences, Immunology, Pharmacotherapy +16